Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb 1;16(3):995-1007.
doi: 10.1158/1078-0432.CCR-09-2553. Epub 2010 Jan 26.

Inherited determinants of ovarian cancer survival

Ellen L Goode  1 , Matthew J Maurer, Thomas A Sellers, Catherine M Phelan, Kimberly R Kalli, Brooke L Fridley, Robert A Vierkant, Sebastian M Armasu, Kristin L White, Gary L Keeney, William A Cliby, David N Rider, Linda E Kelemen, Monica B Jones, Prema P Peethambaram, Johnathan M Lancaster, Janet E Olson, Joellen M Schildkraut, Julie M Cunningham, Lynn C Hartmann
Affiliations

Inherited determinants of ovarian cancer survival

Ellen L Goode et al. Clin Cancer Res. .

Abstract

Purpose: Due to variation of outcome among cases, we sought to examine whether overall survival in ovarian cancer was associated with common inherited variants in 227 candidate genes from ovarian cancer-related pathways including angiogenesis, inflammation, detoxification, glycosylation, one-carbon transfer, apoptosis, cell cycle regulation, and cellular senescence.

Experimental design: Blood samples were obtained from 325 women with invasive epithelial ovarian cancer diagnosed at the Mayo Clinic from 1999 to 2006. During a median follow-up of 3.8 years (range, 0.1-8.6 years), 157 deaths were observed. Germline DNA was analyzed at 1,416 single nucleotide polymorphisms (SNP). For all patients, and for 203 with serous subtype, we assessed the overall significance of each gene and pathway, and estimated risk of death via hazard ratios (HR) and 95% confidence intervals (CI), adjusting for known prognostic factors.

Results: Variation within angiogenesis was most strongly associated with survival time overall (P = 0.03) and among patients with serous cancer (P = 0.05), particularly for EIF2B5 rs4912474 (all patients HR, 0.69; 95% CI, 0.54-0.89; P = 0.004), VEGFC rs17697305 (serous subtype HR, 2.29; 95% CI, 1.34-3.92; P = 0.003), and four SNPs in VHL. Variation within the inflammation pathway was borderline significant (all patients, P = 0.09), and SNPs in CCR3, IL1B, IL18, CCL2, and ALOX5 which correlated with survival time are worthy of follow-up.

Conclusion: An extensive multiple-pathway assessment found evidence that inherited differences may play a role in outcome of ovarian cancer patients, particularly in genes within the angiogenesis and inflammation pathways. Our work supports efforts to target such mediators for therapeutic gain.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Ovarian cancer pathways
Role of angiogenesis, inflammation, detoxification, glycosylation, one-carbon transfer, apoptosis, cell cycle, and cellular senescence pathways in ovarian cancer development.
Figure 2
Figure 2. Covariate-adjusted survival curves by genotype
Genotype-specific survival curves from Cox models using the median clinical risk score as a baseline covariate.
See this image and copyright information in PMC

Similar articles

  • Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.
    Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, Cunningham JM, Rider DN, Preston C, Hartmann LC, Lawrenson K, Wang C, Tyrer J, Song H, deFazio A, Johnatty SE, Doherty JA, Phelan CM, Sellers TA, Ramirez SM, Vitonis AF, Terry KL, Van Den Berg D, Pike MC, Wu AH, Berchuck A, Gentry-Maharaj A, Ramus SJ, Diergaarde B, Shen H, Jensen A, Menkiszak J, Cybulski C, Lubiłski J, Ziogas A, Rothstein JH, McGuire V, Sieh W, Lester J, Walsh C, Vergote I, Lambrechts S, Despierre E, Garcia-Closas M, Yang H, Brinton LA, Spiewankiewicz B, Rzepecka IK, Dansonka-Mieszkowska A, Seibold P, Rudolph A, Paddock LE, Orlow I, Lundvall L, Olson SH, Hogdall CK, Schwaab I, du Bois A, Harter P, Flanagan JM, Brown R, Paul J, Ekici AB, Beckmann MW, Hein A, Eccles D, Lurie G, Hays LE, Bean YT, Pejovic T, Goodman MT, Campbell I, Fasching PA, Konecny G, Kaye SB, Heitz F, Hogdall E, Bandera EV, Chang-Claude J, Kupryjanczyk J, Wentzensen N, Lambrechts D, Karlan BY, Whittemore AS, Culver HA, Gronwald J, Levine DA, Kjaer SK, Menon U, Schildkraut JM, Pearce CL, Cramer DW, Rossing MA, Chenevix-Trench G; AOCS group; ACS; Pharoah PD, Gayther SA, Ness RB, Odun… See abstract for full author list ➔ Charbonneau B, et al. Cancer Immunol Res. 2014 Apr;2(4):332-40. doi: 10.1158/2326-6066.CIR-13-0136. Epub 2014 Jan 27. Cancer Immunol Res. 2014. PMID: 24764580 Free PMC article.
  • Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome.
    White KL, Vierkant RA, Fogarty ZC, Charbonneau B, Block MS, Pharoah PD, Chenevix-Trench G; for AOCS/ACS group;; Rossing MA, Cramer DW, Pearce CL, Schildkraut JM, Menon U, Kjaer SK, Levine DA, Gronwald J, Culver HA, Whittemore AS, Karlan BY, Lambrechts D, Wentzensen N, Kupryjanczyk J, Chang-Claude J, Bandera EV, Hogdall E, Heitz F, Kaye SB, Fasching PA, Campbell I, Goodman MT, Pejovic T, Bean Y, Lurie G, Eccles D, Hein A, Beckmann MW, Ekici AB, Paul J, Brown R, Flanagan JM, Harter P, du Bois A, Schwaab I, Hogdall CK, Lundvall L, Olson SH, Orlow I, Paddock LE, Rudolph A, Eilber U, Dansonka-Mieszkowska A, Rzepecka IK, Ziolkowska-Seta I, Brinton L, Yang H, Garcia-Closas M, Despierre E, Lambrechts S, Vergote I, Walsh C, Lester J, Sieh W, McGuire V, Rothstein JH, Ziogas A, Lubinski J, Cybulski C, Menkiszak J, Jensen A, Gayther SA, Ramus SJ, Gentry-Maharaj A, Berchuck A, Wu AH, Pike MC, Van Denberg D, Terry KL, Vitonis AF, Doherty JA, Johnatty SE, Defazio A, Song H, Tyrer J, Sellers TA, Phelan CM, Kalli KR, Cunningham JM, Fridley BL, Goode EL. White KL, et al. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):987-92. doi: 10.1158/1055-9965.EPI-13-0028. Epub 2013 Mar 19. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 23513043 Free PMC article.
  • The effects of common genetic variants in oncogenes on ovarian cancer survival.
    Quaye L, Gayther SA, Ramus SJ, Di Cioccio RA, McGuire V, Hogdall E, Hogdall C, Blaakr J, Easton DF, Ponder BA, Jacobs I, Kjaer SK, Whittemore AS, Pearce CL, Pharoah PD, Song H. Quaye L, et al. Clin Cancer Res. 2008 Sep 15;14(18):5833-9. doi: 10.1158/1078-0432.CCR-08-0819. Clin Cancer Res. 2008. PMID: 18794094
  • Risk of ovarian cancer and inherited variants in relapse-associated genes.
    Peedicayil A, Vierkant RA, Hartmann LC, Fridley BL, Fredericksen ZS, White KL, Elliott EA, Phelan CM, Tsai YY, Berchuck A, Iversen ES Jr, Couch FJ, Peethamabaran P, Larson MC, Kalli KR, Kosel ML, Shridhar V, Rider DN, Liebow M, Cunningham JM, Schildkraut JM, Sellers TA, Goode EL. Peedicayil A, et al. PLoS One. 2010 Jan 27;5(1):e8884. doi: 10.1371/journal.pone.0008884. PLoS One. 2010. PMID: 20111712 Free PMC article.
  • Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival.
    Song H, Hogdall E, Ramus SJ, Dicioccio RA, Hogdall C, Quaye L, McGuire V, Whittemore AS, Shah M, Greenberg D, Easton DF, Kjaer SK, Pharoah PD, Gayther SA. Song H, et al. Clin Cancer Res. 2008 Feb 15;14(4):1090-5. doi: 10.1158/1078-0432.CCR-07-1195. Clin Cancer Res. 2008. PMID: 18281541 Free PMC article.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49. - PubMed
    1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29. - PubMed
    1. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1992;47:159–66. - PubMed
    1. McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol. 2002;84:399–403. - PubMed
    1. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189:1120–7. - PubMed

Publication types